Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK | Market Cap | 8.63B +1.6% |
| Revenue (ttm) | 834.53M -2.4% |
| Net Income | 73.86M -46.1% |
| EPS | 2.34 -46.1% |
| Shares Out | 31.50M |
| PE Ratio | 117.18 |
| Forward PE | 60.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,208 |
| Average Volume | 115,755 |
| Open | 274.00 |
| Previous Close | 274.00 |
| Day's Range | 272.00 - 278.60 |
| 52-Week Range | 160.00 - 338.00 |
| Beta | 1.42 |
| RSI | 57.23 |
| Earnings Date | Apr 24, 2026 |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi... [Read more]
Financial Performance
In 2025, Xvivo Perfusion AB's revenue was 812.17 million, a decrease of -1.25% compared to the previous year's 822.42 million. Earnings were 25.16 million, a decrease of -85.39%.
Financial StatementsNews
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV): The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusio...
Xvivo Perfusion AB (XVIPF) Q1 2026 Earnings Call Highlights: Strong Organic Growth and Positive ...
Xvivo Perfusion AB (XVIPF) Q1 2026 Earnings Call Highlights: Strong Organic Growth and Positive Cash Flow
Q1 2026 Xvivo Perfusion AB Earnings Call Transcript
Q1 2026 Xvivo Perfusion AB Earnings Call Transcript
Xvivo Perfusion AB Earnings Call Transcript: Q1 2026
Record Q1 sales with 23% organic growth and strong cash flow, driven by robust thoracic and abdominal segment performance. Regulatory milestones for Heart Assist and Liver Assist are progressing, with significant clinical trial successes and expanding adoption in key markets.
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of th...
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Ahead of the Annual General Meeting to be held on 27 April 2026, the Nomination Committee p...
Xvivo Perfusion AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 10% organic growth and record EBITDA margin, with strong performance in thoracic and abdominal segments. Strategic investments and restructuring are set to drive growth in 2026, though profitability will be moderated by expansion efforts. Regulatory milestones for heart and liver products remain key.
Xvivo Perfusion AB Transcript: 44th Annual J.P. Morgan Healthcare Conference
Aims to revolutionize organ transplantation by increasing organ availability and improving outcomes through advanced perfusion technologies. Heart product launch and regulatory milestones are key upcoming drivers, with a strong focus on expanding market reach and service offerings.
Xvivo Perfusion AB Earnings Call Transcript: Q3 2025
Q3 2025 saw 6% organic growth (excluding Heart trial revenue), strong abdominal segment performance, and EBITDA recovery. Strategic investments in U.S. services and partnerships aim to drive future growth, while regulatory timelines for Heart and Liver remain key uncertainties.
Xvivo Perfusion AB Earnings Call Transcript: Q2 2025
Q2 2025 saw negative top-line growth due to lung market slowdown, destocking, and currency headwinds, but strong growth in U.S. lung, kidney, and European liver segments. Regulatory progress and clinical milestones support a positive long-term outlook, with investments focused on field force and production scaling.
Xvivo Perfusion AB Earnings Call Transcript: Q1 2025
Q1 2025 saw strong sales and margin improvements, with key regulatory approvals in the US and Canada. Thoracic and abdominal segments posted double-digit growth, while investments and production expansion support future launches. Cash position remains solid.
Xvivo Perfusion AB Earnings Call Transcript: Q4 2024
Record sales and profitability were achieved in Q4 2024, driven by strong growth in thoracic and abdominal segments, robust clinical adoption, and continued investment in expansion. Regulatory milestones and new product launches are expected to fuel further growth in 2025.
Xvivo Perfusion AB Earnings Call Transcript: Q3 2024
Q3 2024 saw 41% organic sales growth and improved margins, led by strong thoracic and U.S. EVLP performance. Strategic investments in production, clinical trials, and digital services position the company for continued expansion, with new product launches and regulatory milestones ahead.
Xvivo Perfusion AB Earnings Call Transcript: Q2 2024
Record Q2 sales and profitability driven by strong growth in thoracic and abdominal segments, with robust clinical and market momentum. Production scale-up and regulatory progress remain on track, supporting a positive outlook despite seasonal Q3 softness.